Our Work
Latham’s Antitrust Team Achieves Global Regulatory Approvals for AbbVie’s US$10.1 Billion Acquisition of ImmunoGen
February 20, 2024
Strategic deal adds flagship antibody-drug conjugate (ADC) ELAHERE® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to AbbVie's portfolio.
A cross-border Latham & Watkins antitrust team represented AbbVie (NYSE: ABBV) in the company’s now-completed US$10.1 billion acquisition of ImmunoGen (NASDAQ: IMGN). The acquisition accelerates AbbVie's commercial and clinical presence in the solid tumor space. Additionally, ImmunoGen's follow-on pipeline of promising next-generation ADCs further complements AbbVie's ADC platform and existing programs.
Latham successfully obtained approval for the transaction from multiple competition regulators, including the US Federal Trade Commission and Germany’s Federal Cartel Office (Bundeskartellamt).
The firm’s global antitrust team for AbbVie was led by partner Ian Conner and counsel Patrick English in Washington, D.C.; partners Lars Kjølbye and Christos Malamataris in Brussels; partner David Little in London; and partner Max Hauser in Frankfurt; with associates Ehson Kashfipour and Matthew Piehl in Washington, D.C.; Giuseppe Liotine in Brussels; Mark Wagh in London; Markus Welzenbach in Frankfurt; and Hanna Nunez Tse in San Francisco.